Review article: use of induction therapy in liver transplantation (Q38032009)

27 August 2017

title

Review article: use of induction therapy in liver transplantation (English)

1 reference

27 August 2017

main subject

liver transplantation

1 reference

1

Lionel Rostaing

1 reference

27 August 2017

5

Olivier Boillot

1 reference

27 August 2017

3

Yvon Calmus

1 reference

27 August 2017

Faouzi Saliba

2

1 reference

27 August 2017

Sébastien Dharancy

series ordinal

4

1 reference

27 August 2017

publication date

3 August 2012

1 reference

27 August 2017

published in

Transplantation Reviews

1 reference

27 August 2017

volume

26

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

246-260

1 reference

Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Alemtuzumab induction in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Immunosuppression induction with rabbit anti-thymocyte globulin with or without rituximab in 1000 liver transplant patients with long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Screening for basiliximab exposure-response relationships in renal allotransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Immune reconstitution following rabbit antithymocyte globulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Promising early results with immunosuppression using rabbit anti-thymocyte globulin and steroids with delayed introduction of tacrolimus in adult liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Unique histopathological features of graft biopsies with liver function abnormalities in living donor liver transplant patients receiving basiliximab induction therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A safe immunosuppressive protocol in adult-to-adult living related liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

The impact of Campath 1H induction in adult liver allotransplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Alemtuzumab induction in non-hepatitis C positive liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Chronic renal failure after transplantation of a nonrenal organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Tolerogenic immunosuppression for organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Lymphomas after solid organ transplantation: a collaborative transplant study report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

Risk of malignant neoplasms after liver transplantation: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.06.002

10.1016/J.TRRE.2012.06.002

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference